Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://subeta.net
Are you over 18 and want to see adult content?
A complete backup of https://lamaisondesartistes.fr
Are you over 18 and want to see adult content?
A complete backup of https://peterattiamd.com
Are you over 18 and want to see adult content?
A complete backup of https://mugpods.com
Are you over 18 and want to see adult content?
A complete backup of https://espritsnomades.net
Are you over 18 and want to see adult content?
A complete backup of https://combofre.com
Are you over 18 and want to see adult content?
A complete backup of https://vejen-jagtforening.dk
Are you over 18 and want to see adult content?
A complete backup of https://prepawayete.com
Are you over 18 and want to see adult content?
A complete backup of https://will4wheels.com
Are you over 18 and want to see adult content?
A complete backup of https://paper-and-glue.com
Are you over 18 and want to see adult content?
A complete backup of https://spiralytics.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of footlocker-inc.com
Are you over 18 and want to see adult content?
A complete backup of bharatbhasha.com
Are you over 18 and want to see adult content?
A complete backup of thetreatmentcenter.com
Are you over 18 and want to see adult content?
A complete backup of prepareandnourish.com
Are you over 18 and want to see adult content?
Text
Center, CDI
SCIENCE INCUBATOR & ACCELERATOR LABS FOR BIOTECH STARTUPS JLABS in the Press. "South San Francisco, Calif.-based Boost Biomes’ technology works to increase the productivity of beneficial microbes that impact how plants use water and soil nutrients." If you’re driven by something that’s very mission-based, very values-based, then you’re willing to buck the system.IDEA PORTAL
If we have an interest in the subject matter, we may contact you and may thereafter enter into an obligation of confidentiality with you to allow us to obtain more detail or COWORKING LAB SPACE AND BIOTECH INCUBATOR IN TORONTO Coworking Lab Space and Biotech Incubator in Toronto Our JLABS @ Toronto story: In May 2016, Toronto became the sixth JLABS site and the first to be located outside the U.S. Situated right in downtown Toronto within the MaRS Discovery District, North America’s largest urban innovation hub, JLABS @ Toronto is surrounded by researchers, investors, government and entrepreneurs, all IMPROVING DETECTION OF AL AMYLOIDOSIS (IDEA) Why this Challenge Matters. In AL amyloidosis, plasma cells in the bone marrow produce abnormal light chains that form amyloid deposits, which build up in vital organs and eventually cause organ deterioration .AL amyloidosis can affect different organs in different people, but the most frequently affected organs are the heart, kidneys, liver, spleen, GI tract and nervous system.CLAIRE LEURENT
Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. Prior to joining JJDC, Claire was Investment Director, then ManagingDirector, at
BIOTECH INCUBATOR FOR CBRN AND INFECTIOUS DISEASES IN Biotech Incubator for CBRN and Infectious Diseases in Washington, DC. First introduced in conjunction with the launch of the Johnson & Johnson Innovation - JLABS ('JLABS') site opening in Washington, D.C., JLABS @ Washington, DC serves as the hub for Blue Knight. Created in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the ADVANCING NEW HEALTHCARE SOLUTIONS THROUGH COLLABORATIONABOUT USPARTNER WITH USBLOGNEWSCHALLENGESVIDEO HUB Johnson & Johnson Innovation – JLABS @ Washington, DC is designed to support the Johnson & Johnson Innovation mission to curate and cultivate the best early-stage life science innovation wherever it originates. We invite you to explore our space which provides state-of-the-art resources for healthcare startups. 26 April 2021. PARTNERING | JNJ INNOVATION Partnering. We make partnering easy across all of our sectors. Find out how we use our flexible model to partner across our businesses. Learn more. Jnj partnering overview. JOHNSON & JOHNSON INNOVATION Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson. JJDC pursues opportunities to solve critical healthcare needs. Our portfolio companies benefit from the full global capabilities of Johnson & Johnson as we collaborate to drive innovation. CENTER FOR DEVICE INNOVATION The Center for Device Innovation at Texas Medical Center (CDI @ TMC) was founded in 2017 with the mission to significantly impact healthcare by accelerating the development of breakthrough medical technologies. As a collaboration between Johnson & Johnson Medical Devices Companies, Johnson & Johnson Innovation, and the Texas MedicalCenter, CDI
SCIENCE INCUBATOR & ACCELERATOR LABS FOR BIOTECH STARTUPS JLABS in the Press. "South San Francisco, Calif.-based Boost Biomes’ technology works to increase the productivity of beneficial microbes that impact how plants use water and soil nutrients." If you’re driven by something that’s very mission-based, very values-based, then you’re willing to buck the system.IDEA PORTAL
If we have an interest in the subject matter, we may contact you and may thereafter enter into an obligation of confidentiality with you to allow us to obtain more detail or COWORKING LAB SPACE AND BIOTECH INCUBATOR IN TORONTO Coworking Lab Space and Biotech Incubator in Toronto Our JLABS @ Toronto story: In May 2016, Toronto became the sixth JLABS site and the first to be located outside the U.S. Situated right in downtown Toronto within the MaRS Discovery District, North America’s largest urban innovation hub, JLABS @ Toronto is surrounded by researchers, investors, government and entrepreneurs, all IMPROVING DETECTION OF AL AMYLOIDOSIS (IDEA) Why this Challenge Matters. In AL amyloidosis, plasma cells in the bone marrow produce abnormal light chains that form amyloid deposits, which build up in vital organs and eventually cause organ deterioration .AL amyloidosis can affect different organs in different people, but the most frequently affected organs are the heart, kidneys, liver, spleen, GI tract and nervous system.CLAIRE LEURENT
Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. Prior to joining JJDC, Claire was Investment Director, then ManagingDirector, at
BIOTECH INCUBATOR FOR CBRN AND INFECTIOUS DISEASES IN Biotech Incubator for CBRN and Infectious Diseases in Washington, DC. First introduced in conjunction with the launch of the Johnson & Johnson Innovation - JLABS ('JLABS') site opening in Washington, D.C., JLABS @ Washington, DC serves as the hub for Blue Knight. Created in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the ABOUT US | JNJ INNOVATION Mission. Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve peoples’ lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and CENTER FOR DEVICE INNOVATION The Center for Device Innovation at Texas Medical Center (CDI @ TMC) was founded in 2017 with the mission to significantly impact healthcare by accelerating the development of breakthrough medical technologies. As a collaboration between Johnson & Johnson Medical Devices Companies, Johnson & Johnson Innovation, and the Texas MedicalCenter, CDI
JANSSEN BUSINESS DEVELOPMENT If you would like to discuss a collaboration, simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you. Johan Verbeeck, DVM, MsC. Johnson & Johnson Innovation, Janssen Business Development. Email: THE FACES OF THE FUTURE Meet the innovators leading the way in Black Skincare. There’s a reason the saying goes “She’s comfortable in her own skin.” Skin is not only one of the most obvious and memorable features of a person, but also creates an important protective barrier against injury and hazardous substances.WILLIAM E. COHN
Cohn has a passion for medical device development and has more than 90 US patents granted or pending for his medical innovations that have provided the core technology for six venture-backed medical start-ups. A noted cardiovascular surgeon, Dr. Cohn is also a visionary serial inventor. He is a Professor of Surgery at Baylor College of MedicineCLAIRE LEURENT
Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. Prior to joining JJDC, Claire was Investment Director, then ManagingDirector, at
BRUCE R. ROSENGARD
Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy.PIERRE R. THEODORE
Pierre R. Theodore is Vice President, Therapeutic Area Expert, Thoracic Surgical Oncology for Johnson & Johnson Medical Devices Companies. In this role, he is responsible to help accelerate innovation, advance the standard of care within early stage science and to elevate existing and adjacent technologies. Additionally, Dr.Theodore is a
NERIDA SCOTT
Nerida Scott is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center (IC) in London, UK. In this role, Nerida oversees the EMEA IC portfolio of co-investments and collaborations to construct, prioritize and advance the early external innovation portfolio of Johnson & Johnson. QUICKFIRE CHALLENGES JLABS has launched the JLABS San Diego QuickFire Challenge to attract cutting edge, early-stage innovation from around the $25,000 in grant funds. , Consumer Devices, Digital Health, Global Public Health, Therapeutics. Funding.EMIR KAMARIC
Emir Kamaric is a Rice University graduate and has 30 years of experience in the fields of medical device innovations, international clinical trials, surgeon relations and education, in addition to engineering. In partnership with Pfizer-Howmedical and later Stryker, he was engaged in the development and launch of numerous successfulmedical
CLAIRE LEURENT
Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. Prior to joining JJDC, Claire was Investment Director, then ManagingDirector, at
JOHAN L. J. VERBEECK Johan Verbeeck is Vice President, Business Development, Immunology for Johnson & Johnson Innovation, Janssen Business Development. In this role, Johan leads all business development activities for this therapeutic focus area and has accountability for Immunology transactions, acquisitions, scientific licensing and alliancemanagement.
IMPROVING DETECTION OF AL AMYLOIDOSIS (IDEA) Why this Challenge Matters. In AL amyloidosis, plasma cells in the bone marrow produce abnormal light chains that form amyloid deposits, which build up in vital organs and eventually cause organ deterioration .AL amyloidosis can affect different organs in different people, but the most frequently affected organs are the heart, kidneys, liver, spleen, GI tract and nervous system.PIERRE R. THEODORE
Pierre R. Theodore is Vice President, Therapeutic Area Expert, Thoracic Surgical Oncology for Johnson & Johnson Medical Devices Companies. In this role, he is responsible to help accelerate innovation, advance the standard of care within early stage science and to elevate existing and adjacent technologies. Additionally, Dr.Theodore is a
NERIDA SCOTT
Nerida Scott is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center (IC) in London, UK. In this role, Nerida oversees the EMEA IC portfolio of co-investments and collaborations to construct, prioritize and advance the early external innovation portfolio of Johnson & Johnson. BIOTECH INCUBATOR FOR CBRN AND INFECTIOUS DISEASES IN Biotech Incubator for CBRN and Infectious Diseases in Washington, DC. First introduced in conjunction with the launch of the Johnson & Johnson Innovation - JLABS ('JLABS') site opening in Washington, D.C., JLABS @ Washington, DC serves as the hub for Blue Knight. Created in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of theMICHAL PREMINGER
Michal is Head of Johnson & Johnson Innovation, East North America, located at the Innovation Centre in Boston. In this role she leads the Innovation Center team to build, advance, and manage the External R&D portfolio of co-investments spanning across pharmaceutical, consumer health and medical devices. CRISPR & GENE EDITING IN FIGHTING INFECTIOUS DISEASES CRISPR & Gene Editing in Fighting Infectious Diseases. Few technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing, CRISPR in particular, is a latent technology that could change biotech – and we’re just seeing the beginning of what effect it could have on theworld.
OFFICE SPACE FOR HEALTH TECH AND LIFE SCIENCE START-UPS IN The JPOD @ Boston is designed to serve as a health tech industry coworking space for scientist entrepreneurs and life science start-ups in New England. Nestled in the heart of Kendall Square in Cambridge, Massachusetts, and co-located with the Cambridge Innovation Center’s (CIC) newly renovated “launchpad for exceptional entrepreneursEMIR KAMARIC
Emir Kamaric is a Rice University graduate and has 30 years of experience in the fields of medical device innovations, international clinical trials, surgeon relations and education, in addition to engineering. In partnership with Pfizer-Howmedical and later Stryker, he was engaged in the development and launch of numerous successfulmedical
CLAIRE LEURENT
Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. Prior to joining JJDC, Claire was Investment Director, then ManagingDirector, at
JOHAN L. J. VERBEECK Johan Verbeeck is Vice President, Business Development, Immunology for Johnson & Johnson Innovation, Janssen Business Development. In this role, Johan leads all business development activities for this therapeutic focus area and has accountability for Immunology transactions, acquisitions, scientific licensing and alliancemanagement.
IMPROVING DETECTION OF AL AMYLOIDOSIS (IDEA) Why this Challenge Matters. In AL amyloidosis, plasma cells in the bone marrow produce abnormal light chains that form amyloid deposits, which build up in vital organs and eventually cause organ deterioration .AL amyloidosis can affect different organs in different people, but the most frequently affected organs are the heart, kidneys, liver, spleen, GI tract and nervous system.PIERRE R. THEODORE
Pierre R. Theodore is Vice President, Therapeutic Area Expert, Thoracic Surgical Oncology for Johnson & Johnson Medical Devices Companies. In this role, he is responsible to help accelerate innovation, advance the standard of care within early stage science and to elevate existing and adjacent technologies. Additionally, Dr.Theodore is a
NERIDA SCOTT
Nerida Scott is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center (IC) in London, UK. In this role, Nerida oversees the EMEA IC portfolio of co-investments and collaborations to construct, prioritize and advance the early external innovation portfolio of Johnson & Johnson.MICHAL PREMINGER
Michal is Head of Johnson & Johnson Innovation, East North America, located at the Innovation Centre in Boston. In this role she leads the Innovation Center team to build, advance, and manage the External R&D portfolio of co-investments spanning across pharmaceutical, consumer health and medical devices. BIOTECH INCUBATOR FOR CBRN AND INFECTIOUS DISEASES IN Biotech Incubator for CBRN and Infectious Diseases in Washington, DC. First introduced in conjunction with the launch of the Johnson & Johnson Innovation - JLABS ('JLABS') site opening in Washington, D.C., JLABS @ Washington, DC serves as the hub for Blue Knight. Created in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the CRISPR & GENE EDITING IN FIGHTING INFECTIOUS DISEASES CRISPR & Gene Editing in Fighting Infectious Diseases. Few technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing, CRISPR in particular, is a latent technology that could change biotech – and we’re just seeing the beginning of what effect it could have on theworld.
OFFICE SPACE FOR HEALTH TECH AND LIFE SCIENCE START-UPS IN The JPOD @ Boston is designed to serve as a health tech industry coworking space for scientist entrepreneurs and life science start-ups in New England. Nestled in the heart of Kendall Square in Cambridge, Massachusetts, and co-located with the Cambridge Innovation Center’s (CIC) newly renovated “launchpad for exceptional entrepreneurs PARTNERING | JNJ INNOVATION Partnering. We make partnering easy across all of our sectors. Find out how we use our flexible model to partner across our businesses. Learn more. Jnj partnering overview. THE FACES OF THE FUTURE Meet the innovators leading the way in Black Skincare. There’s a reason the saying goes “She’s comfortable in her own skin.” Skin is not only one of the most obvious and memorable features of a person, but also creates an important protective barrier against injury and hazardous substances. SEEKING LIFE-CHANGING I.D.E.A.S. Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Advances in Therapy. 2015;32(10):920-928. McCausland KL, et al. Patient. 2018;11(2):207-216. Merlini G, et al. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492-1495. As appropriate by expertise and/or DECODE – A CLOSER LOOK AT AI FOR PHARMACEUTICALS Q: Dominie, can you please tell us about the Cambridge Innovation Institute and your latest initiative, DECODE: AI for Pharmaceuticals? Dominie: Of course!Cambridge Innovation Institute (CII) works with the goal to deliver cutting-edge information in research while facilitating opportunities for professionals in the life sciences, healthcare, and technology.EMIR KAMARIC
Emir Kamaric is a Rice University graduate and has 30 years of experience in the fields of medical device innovations, international clinical trials, surgeon relations and education, in addition to engineering. In partnership with Pfizer-Howmedical and later Stryker, he was engaged in the development and launch of numerous successfulmedical
JIM TOBIN | JNJ INNOVATION Jim has over 19 years of drug development experience in the areas of hemostasis, inflammation, muscle degenerative diseases, and diabetes. Most recently, Jim was an entrepreneur-in-residence at Atlas Venture and focused on company formation in the life science sector. SCIENCE INCUBATOR & ACCELERATOR LABS FOR BIOTECH STARTUPS JLABS in the Press. "South San Francisco, Calif.-based Boost Biomes’ technology works to increase the productivity of beneficial microbes that impact how plants use water and soil nutrients." If you’re driven by something that’s very mission-based, very values-based, then you’re willing to buck the system.PIERRE R. THEODORE
Pierre R. Theodore is Vice President, Therapeutic Area Expert, Thoracic Surgical Oncology for Johnson & Johnson Medical Devices Companies. In this role, he is responsible to help accelerate innovation, advance the standard of care within early stage scienceand
NERIDA SCOTT
Nerida Scott is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center (IC) in London, UK. In this role, Nerida oversees the EMEA IC portfolio of co-investments and collaborations to construct, prioritize and advance the early external innovation portfolio of Johnson & Johnson.BRUCE R. ROSENGARD
Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy. ADVANCING NEW HEALTHCARE SOLUTIONS THROUGH COLLABORATIONABOUT USPARTNER WITH USBLOGNEWSCHALLENGESVIDEO HUB Johnson & Johnson Innovation – JLABS @ Washington, DC is designed to support the Johnson & Johnson Innovation mission to curate and cultivate the best early-stage life science innovation wherever it originates. We invite you to explore our space which provides state-of-the-art resources for healthcare startups. 26 April 2021. COWORKING LAB SPACE AND BIOTECH INCUBATOR IN TORONTOJEFFERSON LABJLABSJOHNSON AND JOHNSON
Coworking Lab Space and Biotech Incubator in Toronto Our JLABS @ Toronto story: In May 2016, Toronto became the sixth JLABS site and the first to be located outside the U.S. Situated right in downtown Toronto within the MaRS Discovery District, North America’s largest urban innovation hub, JLABS @ Toronto is surrounded by researchers, investors, government and entrepreneurs, all SCIENCE INCUBATOR & ACCELERATOR LABS FOR BIOTECH STARTUPS JLABS in the Press. "South San Francisco, Calif.-based Boost Biomes’ technology works to increase the productivity of beneficial microbes that impact how plants use water and soil nutrients." If you’re driven by something that’s very mission-based, very values-based, then you’re willing to buck the system.CLAIRE LEURENT
Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. Prior to joining JJDC, Claire was Investment Director, then ManagingDirector, at
BRUCE R. ROSENGARD
Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy. JOHAN L. J. VERBEECK Johan Verbeeck is Vice President, Business Development, Immunology for Johnson & Johnson Innovation, Janssen Business Development. In this role, Johan leads all business development activities for this therapeutic focus area and has accountability for Immunology transactions, acquisitions, scientific licensing and alliancemanagement.
BIOTECH INCUBATOR FOR CBRN AND INFECTIOUS DISEASES IN Biotech Incubator for CBRN and Infectious Diseases in Washington, DC. First introduced in conjunction with the launch of the Johnson & Johnson Innovation - JLABS ('JLABS') site opening in Washington, D.C., JLABS @ Washington, DC serves as the hub for Blue Knight. Created in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of theNERIDA SCOTT
Nerida Scott is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center (IC) in London, UK. In this role, Nerida oversees the EMEA IC portfolio of co-investments and collaborations to construct, prioritize and advance the early external innovation portfolio of Johnson & Johnson. OFFICE SPACE FOR HEALTH TECH AND LIFE SCIENCE START-UPS INJOHNSON AND JOHNSON CALIFORNIA LOCATIONSJOHNSON AND JOHNSON INTERNATIONAL LOCATIONSJOHNSON AND JOHNSON LOCATIONS MAPJOHNSON AND JOHNSONLOCATIONS NJ
The JPOD @ Boston is designed to serve as a health tech industry coworking space for scientist entrepreneurs and life science start-ups in New England. Nestled in the heart of Kendall Square in Cambridge, Massachusetts, and co-located with the Cambridge Innovation Center’s (CIC) newly renovated “launchpad for exceptional entrepreneursCAREERS | JLABS
Careers. - Any - JPOD @ Philadelphia JPOD @ Boston JLABS @ Washington, DC JLABS @ Toronto JLABS @ TMC JLABS @ SSF JLABS @ Shanghai JLABS @ San Diego JLABS @ NYC JLABS @ MBC BioLabs JLABS @ M2D2 JLABS @ LabCentral JLABS @ BE. ADVANCING NEW HEALTHCARE SOLUTIONS THROUGH COLLABORATIONABOUT USPARTNER WITH USBLOGNEWSCHALLENGESVIDEO HUB Johnson & Johnson Innovation – JLABS @ Washington, DC is designed to support the Johnson & Johnson Innovation mission to curate and cultivate the best early-stage life science innovation wherever it originates. We invite you to explore our space which provides state-of-the-art resources for healthcare startups. 26 April 2021. COWORKING LAB SPACE AND BIOTECH INCUBATOR IN TORONTOJEFFERSON LABJLABSJOHNSON AND JOHNSON
Coworking Lab Space and Biotech Incubator in Toronto Our JLABS @ Toronto story: In May 2016, Toronto became the sixth JLABS site and the first to be located outside the U.S. Situated right in downtown Toronto within the MaRS Discovery District, North America’s largest urban innovation hub, JLABS @ Toronto is surrounded by researchers, investors, government and entrepreneurs, all SCIENCE INCUBATOR & ACCELERATOR LABS FOR BIOTECH STARTUPS JLABS in the Press. "South San Francisco, Calif.-based Boost Biomes’ technology works to increase the productivity of beneficial microbes that impact how plants use water and soil nutrients." If you’re driven by something that’s very mission-based, very values-based, then you’re willing to buck the system.CLAIRE LEURENT
Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. Prior to joining JJDC, Claire was Investment Director, then ManagingDirector, at
BRUCE R. ROSENGARD
Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy. JOHAN L. J. VERBEECK Johan Verbeeck is Vice President, Business Development, Immunology for Johnson & Johnson Innovation, Janssen Business Development. In this role, Johan leads all business development activities for this therapeutic focus area and has accountability for Immunology transactions, acquisitions, scientific licensing and alliancemanagement.
BIOTECH INCUBATOR FOR CBRN AND INFECTIOUS DISEASES IN Biotech Incubator for CBRN and Infectious Diseases in Washington, DC. First introduced in conjunction with the launch of the Johnson & Johnson Innovation - JLABS ('JLABS') site opening in Washington, D.C., JLABS @ Washington, DC serves as the hub for Blue Knight. Created in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of theNERIDA SCOTT
Nerida Scott is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center (IC) in London, UK. In this role, Nerida oversees the EMEA IC portfolio of co-investments and collaborations to construct, prioritize and advance the early external innovation portfolio of Johnson & Johnson. OFFICE SPACE FOR HEALTH TECH AND LIFE SCIENCE START-UPS INJOHNSON AND JOHNSON CALIFORNIA LOCATIONSJOHNSON AND JOHNSON INTERNATIONAL LOCATIONSJOHNSON AND JOHNSON LOCATIONS MAPJOHNSON AND JOHNSONLOCATIONS NJ
The JPOD @ Boston is designed to serve as a health tech industry coworking space for scientist entrepreneurs and life science start-ups in New England. Nestled in the heart of Kendall Square in Cambridge, Massachusetts, and co-located with the Cambridge Innovation Center’s (CIC) newly renovated “launchpad for exceptional entrepreneursCAREERS | JLABS
Careers. - Any - JPOD @ Philadelphia JPOD @ Boston JLABS @ Washington, DC JLABS @ Toronto JLABS @ TMC JLABS @ SSF JLABS @ Shanghai JLABS @ San Diego JLABS @ NYC JLABS @ MBC BioLabs JLABS @ M2D2 JLABS @ LabCentral JLABS @ BE. ABOUT US | JNJ INNOVATION Mission. Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve peoples’ lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and PARTNERING | JNJ INNOVATION Partnering. We make partnering easy across all of our sectors. Find out how we use our flexible model to partner across our businesses. Learn more. Jnj partnering overview. JOHNSON & JOHNSON INNOVATION Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson. JJDC pursues opportunities to solve critical healthcare needs. Our portfolio companies benefit from the full global capabilities of Johnson & Johnson as we collaborate to drive innovation. DECODE – A CLOSER LOOK AT AI FOR PHARMACEUTICALS Q: Dominie, can you please tell us about the Cambridge Innovation Institute and your latest initiative, DECODE: AI for Pharmaceuticals? Dominie: Of course!Cambridge Innovation Institute (CII) works with the goal to deliver cutting-edge information in research while facilitating opportunities for professionals in the life sciences, healthcare, and technology. SEEKING LIFE-CHANGING I.D.E.A.S. Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Advances in Therapy. 2015;32(10):920-928. McCausland KL, et al. Patient. 2018;11(2):207-216. Merlini G, et al. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492-1495. As appropriate by expertise and/orCHRIS PICARIELLO
Chris joined JJDC in October 2019 from J&J’s North America Consumer organization where he served as Vice President, Finance since July 2017. Prior to this, Chris was Chief Financial Officer and Global Head of Procurement, Government Grants Office and Project Management Office for Janssen Research & Development. He has held roles in finance JIM TOBIN | JNJ INNOVATION Jim has over 19 years of drug development experience in the areas of hemostasis, inflammation, muscle degenerative diseases, and diabetes. Most recently, Jim was an entrepreneur-in-residence at Atlas Venture and focused on company formation in the life science sector.EMIR KAMARIC
Emir Kamaric is a Rice University graduate and has 30 years of experience in the fields of medical device innovations, international clinical trials, surgeon relations and education, in addition to engineering. In partnership with Pfizer-Howmedical and later Stryker, he was engaged in the development and launch of numerous successfulmedical
ELENA FERNANDEZ-KLEINLEIN Elena is responsible for delivering on the goals and objectives for JLABS in Europe. Her responsibilities include P&L management, external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence and educational programming in collaboration with the team responsible for the site and the region.ONE MOMENT...
J&J JUniverse. You can use your username or email address to login.Password
ADVANCING NEW HEALTHCARE SOLUTIONS THROUGH COLLABORATIONABOUT USPARTNER WITH USBLOGNEWSCHALLENGESVIDEO HUB Johnson & Johnson Innovation – JLABS @ Washington, DC is designed to support the Johnson & Johnson Innovation mission to curate and cultivate the best early-stage life science innovation wherever it originates. We invite you to explore our space which provides state-of-the-art resources for healthcare startups. 26 April 2021. COWORKING LAB SPACE AND BIOTECH INCUBATOR IN TORONTOJEFFERSON LABJLABSJOHNSON AND JOHNSON
Coworking Lab Space and Biotech Incubator in Toronto Our JLABS @ Toronto story: In May 2016, Toronto became the sixth JLABS site and the first to be located outside the U.S. Situated right in downtown Toronto within the MaRS Discovery District, North America’s largest urban innovation hub, JLABS @ Toronto is surrounded by researchers, investors, government and entrepreneurs, all SCIENCE INCUBATOR & ACCELERATOR LABS FOR BIOTECH STARTUPS JLABS in the Press. "South San Francisco, Calif.-based Boost Biomes’ technology works to increase the productivity of beneficial microbes that impact how plants use water and soil nutrients." If you’re driven by something that’s very mission-based, very values-based, then you’re willing to buck the system.CLAIRE LEURENT
Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. Prior to joining JJDC, Claire was Investment Director, then ManagingDirector, at
BRUCE R. ROSENGARD
Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy. JOHAN L. J. VERBEECK Johan Verbeeck is Vice President, Business Development, Immunology for Johnson & Johnson Innovation, Janssen Business Development. In this role, Johan leads all business development activities for this therapeutic focus area and has accountability for Immunology transactions, acquisitions, scientific licensing and alliancemanagement.
BIOTECH INCUBATOR FOR CBRN AND INFECTIOUS DISEASES IN Biotech Incubator for CBRN and Infectious Diseases in Washington, DC. First introduced in conjunction with the launch of the Johnson & Johnson Innovation - JLABS ('JLABS') site opening in Washington, D.C., JLABS @ Washington, DC serves as the hub for Blue Knight. Created in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of theNERIDA SCOTT
Nerida Scott is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center (IC) in London, UK. In this role, Nerida oversees the EMEA IC portfolio of co-investments and collaborations to construct, prioritize and advance the early external innovation portfolio of Johnson & Johnson. OFFICE SPACE FOR HEALTH TECH AND LIFE SCIENCE START-UPS INJOHNSON AND JOHNSON CALIFORNIA LOCATIONSJOHNSON AND JOHNSON INTERNATIONAL LOCATIONSJOHNSON AND JOHNSON LOCATIONS MAPJOHNSON AND JOHNSONLOCATIONS NJ
The JPOD @ Boston is designed to serve as a health tech industry coworking space for scientist entrepreneurs and life science start-ups in New England. Nestled in the heart of Kendall Square in Cambridge, Massachusetts, and co-located with the Cambridge Innovation Center’s (CIC) newly renovated “launchpad for exceptional entrepreneursCAREERS | JLABS
Careers. - Any - JPOD @ Philadelphia JPOD @ Boston JLABS @ Washington, DC JLABS @ Toronto JLABS @ TMC JLABS @ SSF JLABS @ Shanghai JLABS @ San Diego JLABS @ NYC JLABS @ MBC BioLabs JLABS @ M2D2 JLABS @ LabCentral JLABS @ BE. ADVANCING NEW HEALTHCARE SOLUTIONS THROUGH COLLABORATIONABOUT USPARTNER WITH USBLOGNEWSCHALLENGESVIDEO HUB Johnson & Johnson Innovation – JLABS @ Washington, DC is designed to support the Johnson & Johnson Innovation mission to curate and cultivate the best early-stage life science innovation wherever it originates. We invite you to explore our space which provides state-of-the-art resources for healthcare startups. 26 April 2021. COWORKING LAB SPACE AND BIOTECH INCUBATOR IN TORONTOJEFFERSON LABJLABSJOHNSON AND JOHNSON
Coworking Lab Space and Biotech Incubator in Toronto Our JLABS @ Toronto story: In May 2016, Toronto became the sixth JLABS site and the first to be located outside the U.S. Situated right in downtown Toronto within the MaRS Discovery District, North America’s largest urban innovation hub, JLABS @ Toronto is surrounded by researchers, investors, government and entrepreneurs, all SCIENCE INCUBATOR & ACCELERATOR LABS FOR BIOTECH STARTUPS JLABS in the Press. "South San Francisco, Calif.-based Boost Biomes’ technology works to increase the productivity of beneficial microbes that impact how plants use water and soil nutrients." If you’re driven by something that’s very mission-based, very values-based, then you’re willing to buck the system.CLAIRE LEURENT
Claire is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston, MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson. Prior to joining JJDC, Claire was Investment Director, then ManagingDirector, at
BRUCE R. ROSENGARD
Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy. JOHAN L. J. VERBEECK Johan Verbeeck is Vice President, Business Development, Immunology for Johnson & Johnson Innovation, Janssen Business Development. In this role, Johan leads all business development activities for this therapeutic focus area and has accountability for Immunology transactions, acquisitions, scientific licensing and alliancemanagement.
BIOTECH INCUBATOR FOR CBRN AND INFECTIOUS DISEASES IN Biotech Incubator for CBRN and Infectious Diseases in Washington, DC. First introduced in conjunction with the launch of the Johnson & Johnson Innovation - JLABS ('JLABS') site opening in Washington, D.C., JLABS @ Washington, DC serves as the hub for Blue Knight. Created in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of theNERIDA SCOTT
Nerida Scott is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center (IC) in London, UK. In this role, Nerida oversees the EMEA IC portfolio of co-investments and collaborations to construct, prioritize and advance the early external innovation portfolio of Johnson & Johnson. OFFICE SPACE FOR HEALTH TECH AND LIFE SCIENCE START-UPS INJOHNSON AND JOHNSON CALIFORNIA LOCATIONSJOHNSON AND JOHNSON INTERNATIONAL LOCATIONSJOHNSON AND JOHNSON LOCATIONS MAPJOHNSON AND JOHNSONLOCATIONS NJ
The JPOD @ Boston is designed to serve as a health tech industry coworking space for scientist entrepreneurs and life science start-ups in New England. Nestled in the heart of Kendall Square in Cambridge, Massachusetts, and co-located with the Cambridge Innovation Center’s (CIC) newly renovated “launchpad for exceptional entrepreneursCAREERS | JLABS
Careers. - Any - JPOD @ Philadelphia JPOD @ Boston JLABS @ Washington, DC JLABS @ Toronto JLABS @ TMC JLABS @ SSF JLABS @ Shanghai JLABS @ San Diego JLABS @ NYC JLABS @ MBC BioLabs JLABS @ M2D2 JLABS @ LabCentral JLABS @ BE. ABOUT US | JNJ INNOVATION Mission. Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve peoples’ lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and PARTNERING | JNJ INNOVATION Partnering. We make partnering easy across all of our sectors. Find out how we use our flexible model to partner across our businesses. Learn more. Jnj partnering overview. JOHNSON & JOHNSON INNOVATION Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson. JJDC pursues opportunities to solve critical healthcare needs. Our portfolio companies benefit from the full global capabilities of Johnson & Johnson as we collaborate to drive innovation. DECODE – A CLOSER LOOK AT AI FOR PHARMACEUTICALS Q: Dominie, can you please tell us about the Cambridge Innovation Institute and your latest initiative, DECODE: AI for Pharmaceuticals? Dominie: Of course!Cambridge Innovation Institute (CII) works with the goal to deliver cutting-edge information in research while facilitating opportunities for professionals in the life sciences, healthcare, and technology. SEEKING LIFE-CHANGING I.D.E.A.S. Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Advances in Therapy. 2015;32(10):920-928. McCausland KL, et al. Patient. 2018;11(2):207-216. Merlini G, et al. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492-1495. As appropriate by expertise and/orCHRIS PICARIELLO
Chris joined JJDC in October 2019 from J&J’s North America Consumer organization where he served as Vice President, Finance since July 2017. Prior to this, Chris was Chief Financial Officer and Global Head of Procurement, Government Grants Office and Project Management Office for Janssen Research & Development. He has held roles in finance JIM TOBIN | JNJ INNOVATION Jim has over 19 years of drug development experience in the areas of hemostasis, inflammation, muscle degenerative diseases, and diabetes. Most recently, Jim was an entrepreneur-in-residence at Atlas Venture and focused on company formation in the life science sector.EMIR KAMARIC
Emir Kamaric is a Rice University graduate and has 30 years of experience in the fields of medical device innovations, international clinical trials, surgeon relations and education, in addition to engineering. In partnership with Pfizer-Howmedical and later Stryker, he was engaged in the development and launch of numerous successfulmedical
ELENA FERNANDEZ-KLEINLEIN Elena is responsible for delivering on the goals and objectives for JLABS in Europe. Her responsibilities include P&L management, external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence and educational programming in collaboration with the team responsible for the site and the region.ONE MOMENT...
J&J JUniverse. You can use your username or email address to login.Password
We use cookies on this site to enhance your user experience. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy . If you agree to our use of cookies and legal notice, you can continue to useour site.
Accept Skip to main content Visit our other sites* jnj.com
* jnjinnovation network * Innovation Centers* JLABS
* JJDC
* Janssen Business Development * Quickfire Challenges____
MAIN NAVIGATION
* " class="is-active">Home* About us
* Mission
* Network
* Leadership
* Partner with us
* Pharmaceuticals
* Medical Devices
* Consumer Health
* Global Public Health* Blog
* News
* All news
* Press releases
* In the media
* Partner news
* Social
* Other News
* Challenges
* Video hub
* Connect with Us
* Locations & Contacts* Digital Brochure
* Meet with us
* Subscribe
ADVANCING NEW HEALTHCARE SOLUTIONS THROUGH COLLABORATION Consumer - Medical Devices - Pharmaceuticals - Global Public Health PUTTING A SPOTLIGHT ON JOHNSON & JOHNSON INNOVATION Are you familiar with all the tools in our toolkit? Take a look at our infographic where we've put a spotlight on our work in Asia Pacific10 May 2021
ANNOUNCING THE VETERANS LEAD QUICKFIRE CHALLENGE: INNOVATIONS BY VETS U.S. Veteran innovators and military spouses are invited to submit potentially ground-breaking ideas in all aspects of human healthcare for the chance to receive grant funding from up to a total of $250K, access to the global Johnson & Johnson Innovation - JLABS ecosystem, and mentorship from experts across the Johnson & Johnson Family ofCompanies.
02 June 2021
WE’RE OPEN FOR BUSINESS! A FIRST LOOK AT JLABS @ WASHINGTON, DC We’re happy to share that we’ve opened our doors. Johnson & Johnson Innovation – JLABS @ Washington, DC is designed to support the Johnson & Johnson Innovation mission to curate and cultivate the best early-stage life science innovation wherever it originates. We invite you to explore our space which provides state-of-the-art resources for healthcare startups.26 April 2021
OUR COVID-19 RESPONSE Johnson & Johnson Innovation is committed to helping patients, our partners and communities around the world manage the unprecedentedimpact of COVID-19.
17 December 2020
Johnson & Johnson Innovation LLC 2021. All Rights Reserved. Your use of the information on this site is subject to the terms of our Legal Notice . Please see our Privacy Policy and Do Not Sell My Personal Information form. This site is published by Johnson & Johnson Innovation LLC which is solely responsible for its contents. This site is intended for global audiences. Capitalized product names are trademarks of the Johnson & Johnson Family of Companies or its affiliates.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0